Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00194649 · ClinicalTrials.gov registry record · Phase 4
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
A Phase 4 study of Contraception, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00194649: Completed Phase 4 study of Contraception, sponsored by University of Washington.
NCT00194649 is a Phase 4 study of Contraception that has completed, run by University of Washington. The registered enrollment target is 8 participants, below the 455-participant average among 72 other Contraception trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00194649, a Phase 4 study of Contraception, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive.
Conditions Studied
Interventions
- DRUG Miglustat (Zavesca)
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
What the finished NCT00194649 record still lists
NCT00194649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 455-participant average among 72 other Contraception trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which Miglustat (Zavesca) is the first listed.
NCT00194649 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00194649 about?
NCT00194649 is a clinical study titled "Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)". The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male c...
What is the current status of trial NCT00194649?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2005-06. Estimated completion is 2006-01.
What conditions does trial NCT00194649 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT00194649?
The interventions under investigation include: Miglustat (Zavesca) (DRUG).
Who is sponsoring clinical trial NCT00194649?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00194649 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00194649's enrollment target sits among peer trials
8 72nd of 72 higher than 1 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
RECRUITING · Phase 4
-
Etonogestrel Implant as Emergency Contraception
RECRUITING · Phase 4
-
RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Combined Hormonal Contraceptives on UPA
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia